Stay updated on M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial page.

Latest updates to the M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page’s displayed software/version label is updated from v3.5.2 to v3.5.3, reflecting a maintenance or release revision without changing the study record details.SummaryDifference0.1%

- Check25 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 from the history.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision: v3.5.0 was added and revision v3.4.3 was removed.SummaryDifference0.1%

- Check61 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 in the history. No substantive content changes are evident from the screenshots.SummaryDifference0.1%

- Check90 days agoChange DetectedRevision: v3.4.2 was added to the history; older notices (v3.4.1 and a government funding banner) were removed. These updates affect the UI/site banners rather than the clinical trial content.SummaryDifference0.5%

- Check97 days agoChange DetectedA system-wide funding notice was added to the page and the revision version updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

Stay in the know with updates to M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the M7824 Versus Pembrolizumab in 1L PD-L1+ NSCLC Clinical Trial page.